<DOC>
	<DOCNO>NCT01358357</DOCNO>
	<brief_summary>This multi-center , randomize , placebo-controlled , flexible-dose , parallel-group study design evaluate efficacy safety lurasidone ( combination lithium divalproex ) maintenance treatment bipolar I disorder subject without rapid cycling /or psychotic feature .</brief_summary>
	<brief_title>Bipolar Maintenance Study Lurasidone Adjunctive Lithium Divalproex</brief_title>
	<detailed_description>This study evaluate efficacy safety lurasidone ( combination lithium divalproex ) maintenance treatment bipolar I disorder subject without rapid cycling and/or psychotic feature .</detailed_description>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Openlabel Phase 18 year age old Diagnostic Statistical Manual Mental Disorders , 4th Ed. , Text Revision ( DSMIVTR ) diagnosis bipolar I disorder •≥ 1 manic , mixed manic , depress episode past 2 year YMRS MADRS total score ≥ 14 lithium divalproex ; ≥ 18 lithium divalproex Doubleblind Phase Subjects must achieve consistent clinical stability , define total score ≤ 12 YMRS MADRS least 12 week , allowance two excursion ( YMRS and/or MADRS total score 13 14 , respectively ) except last 4 week randomization Open Label Phase Diagnosis Axis I Axis II disorder , bipolar I disorder , primary focus treatment within 3 month screen Subjects diagnostic agreement Investigator United BioSource Corporation ( Boston ) ( UBC ) reach Ultrafast rapid cycling ( define ≥ 8 mood episode previous 12month period ) Subjects test positive drug abuse screen . In event subject test positive cannabinoids ( tetrahydrocannabinol ) , Investigator evaluate subject 's ability abstain cannabis study Unstable/inadequately treat medical illness The subject answer `` yes '' `` Suicidal Ideation '' item 4 5 CSSRS ( time evaluation ) Double Blind Phase Subjects Investigator 's judgment compliant study medication stabilization phase Subjects stabilize openlabel phase ( within 20 week ) Subjects test positive drug abuse doubleblind phase baseline . In event subject test positive cannabinoids ( tetrahydrocannabinol ) , Investigator evaluate subject 's ability abstain cannabis study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
	<keyword>Bipolar I</keyword>
</DOC>